IMMB 0.00 Immunotech Laboratories, Inc.
| Range: | 1.0E-6-0.0062 | Vol Avg: | 15600 | Last Div: | 0 | Changes: | 0 |
| Beta: | -54.92 | Cap: | 0.00B | Currency: | USD | Exchange: | PNK |
| Sector: | Healthcare | IPO: | Thu Dec 01 2022 | Empoloyees: | 4 | ||
| CUSIP: | CIK: | ISIN: | US45254F2039 | Country: | US | ||
Immunotech Laboratories, Inc. develops and commercializes proprietary proteins for use in treating human immunodeficiency virus (HIV), acquired immune deficiency syndrome (AIDS), hepatitis, and other immuno-related disorders. Its flagship compound is ITV-1 (immune therapeutic vaccine), a suspension of irreversible pepsin fraction that is used in the treatment of HIV/AIDS and Hepatitis C, as well as to modulate the immune system. The company is headquartered in Monrovia, California. As of June 14, 2017, Immunotech Laboratories, Inc. operates as a subsidiary of Eco-Petroleum Solutions, Inc.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow